

SymBio Pharmaceuticals

Corporate update

New formulations extend Treakisym patent life

SymBio has substantially increased the value of its Treakisym franchise through in-licencing novel bendamustine formulations from Eagle Pharmaceuticals for \$12.5m. The new formulations bring a lower cost of goods and 10 years of additional patent protection to help in life cycle management of the Treakisym franchise. Sales of Treakisym following the approval of two new indications in 2016 have exceeded the company's expectations, leading it to upgrade FY17 sales guidance. Interim data from the global Phase III rigosertib trial could become available during Q417. We value SymBio at ¥19.7bn (unchanged), with the enhanced Treakisym portfolio offsetting the suspension of IONSYS development.

Year end	Revenue (¥m)	PBT* (¥m)	EPS* (¥)	DPS (¥)	P/E (x)	Yield (%)
12/15	1,933	(2,630)	(81.33)	0.0	N/A	N/A
12/16	2,368	(2,317)	(59.00)	0.0	N/A	N/A
12/17e	3,599	(4,000)	(84.74)	0.0	N/A	N/A
12/18e	4,248	(2,003)	(41.84)	0.0	N/A	N/A

Note: *PBT and EPS (diluted) are normalised, excluding exceptional items.

Replicating Teva's strategy to maintain market share

SymBio has in-licensed two liquid formulations of bendamustine hydrochloride (Treakisym) to complement its marketed lyophilised/dry powder product: a ready-to-dilute (RTD) formulation and a rapid infusion (RI) formulation that will cut drug infusion time from 60 minutes to 10 minutes. Patents on the RTD and RI formulations extend to 2031, whereas orphan exclusivity on Treakisym powder expires in October 2020. SymBio is aiming to replicate the strategy that has seen Teva transfer 97% of bendamustine HCl sales in the US to the RI formulation.

Initiated Treakisym Phase III in r/r DLBCL

In August SymBio initiated a Phase III trial of Treakisym relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL), an intermediate or high-risk form of non-Hodgkin's lymphoma (NHL), which represents a market of around 11,000 patients in Japan. We model a potential launch in H220.

SymBio could market Treakisym alone after 2020

The current marketing agreement with Eisai for Treakisym runs until late 2020. Although SymBio has not announced definitive plans for the marketing arrangements for Treakisym post 2021, SymBio may elect to market Treakisym alone, with its own sales infrastructure. We estimate that self-commercialisation of Treakisym would add ~¥8.6bn (\$78m) to our base-case valuation.

Valuation: rNPV of ¥19.7bn (\$174m) or ¥410/share

Our risk-adjusted valuation is ¥19,672m (\$174m) or ¥410/share (vs ¥19,744m). We have revised our forecasts to account for: greater market share and improved profit margins for Treakisym liquid formulations from 2021 onwards, offset by anticipated ¥1.5bn development costs; risk-adjusted revenues and ¥2.0bn development costs for the new DLBCL indication; the 23% increase in 2017 Treakisym sales guidance; and suspension of development of the IONSYS pain product.

Pharma & biotech

23 October 2017

Price **¥230**

Market cap **¥11,270m**

Net cash (¥m) at end June 2017 4,885

Shares in issue 49.0m

Free float 76%

Code 4582

Primary exchange Japan

Secondary exchange OTC US

Share price performance



% 1m 3m 12m

Abs (1.7) (8.4) (3.4)

Rel (local) (5.3) (13.5) (23.5)

52-week high/low ¥311.0 ¥200.0

Business description

SymBio Pharmaceuticals is a Japanese specialty pharma company with a focus on oncology and haematology. The Treakisym powder formulation was in-licensed from Astellas in 2005; liquid Treakisym was in-licensed from Eagle Pharmaceuticals in 2017. Rigosertib was in-licensed from Onconova.

Next events

Rigosertib iv Phase III interim data H217

In-licensing activities TBD

Treakisym sales update Q417

Analysts

Dennis Hulme +61 (0)2 9258 1161

Maxim Jacobs +1 646 653 7027

healthcare@edisongroup.com

[Edison profile page](#)

SymBio Pharmaceuticals is a research client of Edison Investment Research Limited

Liquid formulations enhance Treakisym franchise

SymBio has in-licensed two liquid formulations from Eagle Pharmaceuticals (Eagle) to strengthen its Treakisym (bendamustine HCl) franchise. Terms included \$12.5m upfront, undisclosed potential future milestones (we model \$10m) and a royalty on sales. The new formulations are more convenient for healthcare workers and patients, and are protected by patents that extend to 2031, whereas orphan exclusivity on the company's currently marketed lyophilised (freeze-dried) dry powder Treakisym product expires in October 2020.

The Treakisym lyophilised powder has to be reconstituted before administration, which is time consuming and carries the risk of exposing healthcare workers to cytotoxic powders and vapours.

The first in-licensed product is an RTD liquid formulation that will make dose preparation easier and safer for health professionals. The drug is administered to the patient as a 60-minute infusion in the same way as the current Treakisym product.

The second in-licensed product is an RI formulation that will cut drug infusion time to 10 minutes from 60 minutes for the current Treakisym product.

Strategy designed to maintain SymBio's market share

SymBio is in discussions with the regulators about the data that would be required to achieve registration for the two liquid formulations.

The RTD product is expected to be the first of the two products approved. Depending on the outcome of ongoing discussions with regulators, SymBio expects a reduced development period before filing for approval given that the same drug compound is being administered to patients in the same manner – the only difference is the way that the iv infusion is prepared.

The RI product represents a greater change to the current treatment protocols, so approval of this product is expected to take longer. It is reasonable to expect that a small clinical study of perhaps 40-60 patients would be required in order to confirm that the pharmacokinetics and safety of the 10-minute infusion are comparable to the currently approved 60-minute infusion of Treakisym.

SymBio is aiming to launch the RTD product in January 2021. It is targeting approval of the RI formulation later in H121, which could potentially allow a launch in Q321 or January 2022. Orphan exclusivity for Treakisym expires in October 2020, which means that the first generic copies of the Treakisym powder could be launched as early as the start of 2022.

SymBio is pursuing a similar strategy to that adopted by Teva in the US, where it markets bendamustine HCl under the brand names Treanda and Bendeka. Teva developed its own RTD Treanda formulation, and in-licensed the RI bendamustine HCl formulation from Eagle that it now markets as Bendeka.

Teva launched an RTD liquid formulation of Treanda in November 2014; it launched the Bendeka RI product in January 2016, and subsequently withdrew the RTD liquid Treanda from the market in March 2016. Lyophilised Treanda powder for injection is still available, but its use has substantially declined in favour of Bendeka. Teva said in August 2017 that Bendeka is the most-used bendamustine product in the US market. Eagle disclosed in a corporate presentation in September that Bendeka has achieved a 97% market share in the US, which is testament to the appeal of the short infusion time.

The first generic copies of Treanda powder are expected to be launched in the US in 2019. The market share that Bendeka can maintain in the face of competition from powder generics will be a useful guide to how successful the strategy could be for SymBio.

In contrast to the situation for Teva, SymBio may have only 12 months to convert clinicians to using the liquid Treakisym formulations before the launch of the first Treakisym powder generics. This shorter time period creates additional uncertainty as to how large a market share the RTD and RI products will be able to gain before they potentially face competition from powder generics in 2022.

In our forecasts we model SymBio's strategy being quite successful at maintaining market share, with dry powder Treakisym generics slowly growing market share from 2022 onwards to reach a 25% market share by 2031. We model the growth in Treakisym generics' market share accelerating in 2032 after the patents on the liquid formulations expire.

In our scenario analysis on page 7, we note that if Treakisym generics were to gain a 50% market share by 2031 (vs 25%), this would remove around ¥1.5bn (¥31/share) from our valuation.

Improved commercial terms and opportunity to self-commercialise

We believe that the cost of goods under the Eagle licence agreement will be lower than under the current arrangements with Astellas for the Treakisym powder formulation, which would lift profit margins for SymBio once the liquid formulations are launched.

Furthermore, SymBio has previously announced its intention to eventually develop its own salesforce to commercialise drug products in Japan. Given that the current licence agreement with Eisai for commercialising Treakisym runs until 2020, SymBio would have the opportunity to self-commercialise Treakisym after 2020, including the new liquid formulations, should it choose to do so.

SymBio has not announced any definitive plans for the commercialisation strategy for Treakisym after 2020. In our view, the four main options are:

- self-commercialisation;
- license to Eisai under renegotiated terms;
- license to a third party; or
- a combination of self-commercialisation and a licensing arrangement.

We would expect each of these four options to generate higher profit margins for SymBio than the current commercialisation arrangements with Eisai. Combining this with the lower cost of goods under the Eagle licence agreement, we model a significant lift in profit margins on Treakisym sales after 2020.

DLBCL Phase III trial initiated

Treakisym is currently approved in Japan for chronic lymphocytic leukaemia (CLL) and for first-line and r/r patients with low-grade non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma (MCL).

SymBio is seeking to add an additional indication for the treatment of r/r DLBCL, an intermediate or high-risk form of NHL. After consultation with the Pharmaceuticals and Medical Devices Agency, SymBio commenced a Phase III trial in August to confirm the safety and efficacy of Treakisym (bendamustine HCl) plus rituximab in DLBCL. Our model assumes continued development with a potential launch in H220.

SymBio completed a Phase II study for Treakisym plus rituximab in r/r DLBCL in 2012. An analysis of 59 cases in the Phase II study showed an encouraging ORR of 62.7% and CR of 37.3%.

The higher market share expected for branded Treakisym liquid formulations post 2020 has increased the potential value of the DLBCL indication to SymBio, and has made the expense of the DLBCL Phase III trial worthwhile (we model Phase III costs of ¥2bn).

Overview of DLBCL

DLBCL is a rapidly-growing, intermediate or high-risk form of NHL, in contrast to the slower-growing indolent or low-risk lymphomas that are included in the current approval for Treakisym. There is currently no standard chemotherapy for the treatment of DLBCL. Patients are typically treated with multiple drug therapies including:

- CHOP – Cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine, and prednisone;
- R-CHOP – CHOP plus rituximab; and
- Dose-adjusted EPOCH-R – etoposide, prednisone, vincristine [Oncovin], cyclophosphamide, doxorubicin, plus rituximab.

Although DLBCL is an aggressive lymphoma, the rapidly growing cells are often susceptible to chemotherapy and a significant proportion of patients can be cured by first-line chemotherapy treatments. Unfortunately, a majority of patients relapse, typically within two years of the initial treatment. Patients who relapse or are refractory to first-line treatment have an extremely poor prognosis. A range of salvage chemotherapy regimens are used in relapse therapy.

DLBCL indication could almost double Treakisym peak sales potential.

DLBCL is the most common form of NHL, so it represents a large addressable market for Treakisym.

While DLBCL is estimated to represent 30-40% of all cases of NHL worldwide, an epidemiology study by Chihara et al¹ found that DLBCL comprised a much higher proportion of NHL cases in Japan than it does in the US (45% vs 28%). The study also found that the incidence of NHL was much higher in the US than it was in Japan (2.8x higher in the US in 2008), but that the incidence in Japan was rising rapidly, growing by 6.8% per year.

Globocan estimates that there were ~21,000 new cases of NHL Japan in 2012. Applying the 6.8% annual growth rate to the 2012 Globocan estimate, we project that there will be 35,500 new cases of NHL and 16,000 new cases of DLBCL in Japan in 2020. Assuming that 70% of DLBCL patients progress to receive second line therapy, we forecast a target market of 11,200 second-line DLBCL patients per year in Japan by 2020.

The patient market of 11,200 r/r DLBCL patients in Japan is almost as large as the combined market of ~12,500 patients for the currently approved indications for Treakisym in CLL and first-line and r/r low-grade NHL and MCL patients. We model peak sales of ¥11bn for the DLBCL vs ¥13.5bn for the currently approved indications.

Rigosertib iv interim Phase III analysis expected Q417

SymBio in-licensed rigosertib (iv and oral formulations, Japan and Korean rights) from [Onconova](#) in 2011 for MDS (myelodysplastic syndromes), a rare blood cancer. SymBio is contributing patients from Japan to the 225-patient global [Phase III INSPIRE](#) trial of iv rigosertib for the treatment of second-line HR-MDS (higher-risk MDS).

According to Onconova, an interim analysis is expected during Q417. The interim analysis will be performed after 88 events (deaths) have occurred, and will examine overall survival in the intent to treat population (ITT). For a trial to be stopped for efficacy at an interim analysis would usually require a much higher statistical hurdle than at the full analysis (ie generally $p < 0.05$). Top-line data from the full analysis after 176 events is expected in H118; however, Onconova commented in August that enrolment for the trial has slowed recently, which it said could be related to seasonality.

1 Chihara et al; [British Journal of Haematology](#), 2014, 164, 536–545; doi: 10.1111/bjh.12659

If enrolment does not return to desired levels, then full enrolment could be delayed by several months.

The INSPIRE trial has been designed following analysis of the failed [Phase III ONTIME](#) trial of iv rigosertib in HR-MDS. In the ONTIME trial, iv rigosertib failed to meet the primary endpoint, although it did show benefits in certain subgroups.

Patient recruitment in INSPIRE has been refined to HR-MDS patients who: have failed HMA² (hypomethylating agent) treatment within nine months of HMA initiation; are younger than 82 years of age; and received their last HMA dose within the six months prior to entering the INSPIRE trial. In the ONTIME trial, iv rigosertib was able to improve survival in this particular patient group (data summarised in Exhibit 1). Hence, the trial design and recruitment criteria have been selected to try to improve the likelihood of INSPIRE trial success.

Exhibit 1: Median overall survival (OS) in the ONTIME trial					
		Median OS	N	Hazard ratio	p value
ONTIME trial	Rigosertib	8.2 months	199	0.87	0.33
	BSC	5.9 months	100	(95% CI: 0.67-1.14)	
ONTIME subset (as per INSPIRE inclusion criteria)	Rigosertib	7.9 months	77	0.48	0.0008
	BSC	4.1 months	39	(95% CI: 0.31-0.74)	

Source: Onconova, *The Lancet Oncology* 2016 (17): 496–508

If the interim analysis is positive, then partner Onconova may need to seek additional financing to complete the INSPIRE trial; this follows partner Baxter, which was funding half the trial costs, returning all rigosertib rights in March 2016.

IONSYS development suspended

In October 2015 SymBio acquired an exclusive licence in Japan to develop and market IONSYS (SyB P-1501) for the short-term management of acute post-operative pain from The Medicines Company. SymBio initiated a Phase III trial in Japan in June 2016, with the first patient recruited in November of that year; top-line data had been expected in Q317.

In May SymBio announced that it had temporarily suspended enrolment in the IONSYS Phase III trial. In June 2017 The Medicines Company announced that it was voluntarily withdrawing IONSYS from sale in the US market. Given that The Medicines Company was to supply the patches to SymBio, it will be challenging for SymBio to continue development of IONSYS.

SymBio is continuing to discuss with The Medicines Company the effects of its decision to withdraw IONSYS from the US market and we would expect SymBio may seek to recover damages. No announcement has been made.

We have removed the IONSYS program from our valuation model. We had previously valued the program at ¥5.9bn.

Sensitivities

SymBio is subject to the usual drug development risks, including clinical development delays or failures, regulatory risks, competitor successes, partnering setbacks, financing and commercial

² HMA failures are defined as patients who have progressed, failed or relapsed following treatment with either Vidaza (azacitidine) or Dacogen (decitabine), the US approved HMAs. Only Vidaza is approved in Japan.

risks. The main sensitivities include rigosertib and DLBCL clinical trial success or failure, and the ability to execute future in-licensing deals.

For Treakisym, key risks relate to the outcome of the DLBCL Phase III trial, obtaining regulatory approval for the liquid Treakisym formulations, and success in migrating patients to the liquid formulation to stave off competition from generic copies of Treakisym powder after 2021. The commercialisation arrangements for Treakisym after 2020 (licence vs self-commercialise) will influence profit margins on the product.

With a recent focus on oncology drug prices in Japan, Treakisym pricing could come under scrutiny. Our current forecasts assume stable pricing; any price cuts could therefore adversely affect our sales projections.

SymBio is in discussions with The Medicines Company about the impact of its decision to voluntarily withdraw IONSYS from the US market. We do not currently model any compensation payments in regards to IONSYS, so if SymBio was to receive any compensation, this would represent potential to recover some of the value now written off by Edison.

The main sensitivity for rigosertib in 2017 will be the outcome of the pre-planned interim analysis of the Phase III INSPIRE trial of iv rigosertib in second-line HR-MDS, which partner Onconova expects during Q417. If the outcome is positive and the trial proceeds as planned, Onconova may need additional cash to continue funding the trial beyond the end of 2017; top-line data are expected in H118, although enrolment has slowed recently, which could potentially delay top-line data. If Onconova is unable to secure additional funds, this could also delay trial completion and therefore timelines. If the outcome of the interim analysis is negative, then not only would this have an impact on iv rigosertib development, but there could also be read-across to oral rigosertib.

SymBio is reliant on in-licensing further assets to fill its pipeline. We believe the CEO's network is crucial to securing future deals, although we have limited visibility on the potential terms and timing of any such agreements.

Valuation

Our valuation of SymBio is virtually unchanged at ¥19,672m (\$174m), or ¥410/share, based on a risk-adjusted NPV analysis, which includes ¥5,269m (\$47m) net cash at end December 2016. We use a 10% discount rate for approved products and 12.5% elsewhere. Our valuation includes Treakisym approved indications and the new DLBCL indication, plus rigosertib. We have rolled our valuation model forward in time and have made a number of adjustments to our main assumptions, which are summarised in Exhibit 2 below.

Exhibit 2: SymBio rNPV valuation

Product	Indication	Launch	Peak sales (¥m)	NPV (¥m)	Probability	rNPV (¥m)	NPV/share (¥/share)
Treakisym	LG NHL/MCL (r/r and 1st line); CLL	2010*	13,500	11,728	100-95%	11,274	235.1
Treakisym (DLBCL)	r/r DLBCL	2021	11,000	4,086	60%	1,767	36.8
Rigosertib (IV)	r/r HR-MDS	2020	3,400	2,126	50%	825	17.2
Rigosertib (oral)	LR-MDS (mono) or First-line HR-MDS (combo)	2022	7,500	3,745	25%	536	11.2
Net cash at 30 December 2016				5,269	100%	5,269	109.9
Valuation				26,955		19,672	410.2

Source: Edison Investment Research. Note: *Treakisym was launched in 2010 in r/r low-grade NHL/MCL; it received approvals in Japan in CLL in August 2016 and in first-line, low-grade NHL/MCL in December 2016.

We model a 95% likelihood that the RI Treakisym formulation will be launched by the start of 2023, thereby minimising the penetration of generic copies of the Treakisym powder formulation. We model Treakisym market share slowly declining to 75% in 2031, followed by a more rapid decline

from 2032 after the liquid formulation patents expire. We previously modelled Treakisym sales to decline by 30% in 2021 and 15% per year in subsequent years.

Our Treakisym valuation continues to assume that SymBio earns an average net margin of 10-12% on top-line reported Treakisym sales until 2020. However, we now assume that after 2020 the net operating margin gradually increases to reach 25% in 2023 and subsequent years as liquid formulations in-licensed from Eagle gain market share. We believe that this higher margin is achievable through a combination of a lower COGS and/or higher revenue share for SymBio.

We now model ¥1.5bn of development costs to achieve approval for the RTD and RI liquid formulations of Treakisym.

We have added sales in r/r DLBCL (aggressive NHL) to our forecasts, as described earlier in this report. We now include potential peak sales of ¥11.0bn in this indication, with a 60% probability and a 12.5% discount rate. We also model development costs of ¥2.0bn for DLBCL.

We have maintained our peak sales assumptions and probabilities of success for rigosertib (iv and oral). However, we now model a higher COGS for rigosertib, which we believe better reflects the costs that SymBio would be likely to incur under the agreement with Onconova.

Following the suspension of development of IONSYS, we have removed all future costs and revenues from the product from our model. Any compensation payments from The Medicines Company would represent upside to our forecasts and valuation.

Our base-case forecasts assume that SymBio earns a net operating margin of 25% on Treakisym net sales from 2023 onwards. Should SymBio choose to establish its own salesforce to self-commercialise Treakisym after 2020, we estimate that it could achieve an operating margin of 50% on Treakisym sales by 2025. Under this scenario our valuation would increase by around ¥8.6bn (¥160/share) to around ¥27bn (¥570/share).

On the other hand, in a scenario where the Treakisym market share declines to 50% by 2031 (vs 75% for the base case), our valuation would fall by around ¥1.5bn (¥31/share) to around ¥18.1bn (¥379/share).

We currently assume stable Treakisym pricing. However, should Treakisym be subject to a price cut in the future, this could represent downside to our forecasts; a 10% price cut in 2018 would remove around ¥1.6bn from our Treakisym rNPV, or ¥34/share.

Financials

Our financial forecasts have been updated to reflect Q217 reported financials and SymBio's updated financial guidance for 2017, including the 23% increase in 2017 Treakisym sales guidance. Our Treakisym forecasts have also increased in 2018 given the higher base in 2017. The main changes to our forecasts are summarised in Exhibit 3.

We have increased SG&A expenses to reflect the 28% growth in H117. We have included the \$12.5m (¥1.4bn) Eagle Pharmaceuticals upfront payment and forecast R&D spending on RTD and RI formulations of Treakisym. We have removed all future revenue and costs associated with the IONSYS program from our forecasts.

We estimate current cash should be sufficient to fund operations into H218, by which point the Phase III clinical trial for rigosertib iv should be complete. We model ¥950m of indicative debt in FY18.

Exhibit 3: Main changes to our financial forecasts

¥m	2017	2017	% change	2018	2018	% change
	Old	New		Old	New	
Revenue	2,902	3,599	+24%	3,820	4,248	+11%
Research and development	(2,300)	(3,145)	+37%	(1,600)	(1,350)	-16%
Selling, general and administration	(1,750)	(1,850)	+6%	(1,837)	(1,924)	+5%
Operating profit (reported)	(3,191)	(3,930)	+23%	(2,306)	(2,017)	-13%
Profit before tax (reported)	(3,261)	(4,000)	+23%	(2,284)	(2,003)	-12%
Profit after tax (reported)	(3,264)	(4,003)	+23%	(2,288)	(2,006)	-12%

Source: Edison Investment Research

Exhibit 4: SymBio's original and revised 2017 outlook versus our estimates

	Previous 2017 guidance	Revised 2017 guidance	2017 estimates	Difference
Revenue	¥2,903m	¥3,583m	¥3,599m	-¥16m
Operating loss	¥3,238m	¥3,932m	¥3,930m	¥2m
Ordinary loss	¥3,303m	¥4,009m	¥4,000m	¥9m
Net loss	¥3,306m	¥4,009m	¥4,003m	¥6m

Source: SymBio Pharmaceuticals and Edison Investment Research

Exhibit 5: Financial summary

Accounts: JPN GAAP; Year-end: 31 December; ¥m	2013	2014	2015	2016	2017e	2018e
Profit & loss						
Total revenues	1,532	1,955	1,933	2,368	3,599	4,248
Cost of sales	(1,214)	(1,428)	(1,350)	(1,464)	(2,534)	(2,991)
Gross profit	318	527	583	904	1,065	1,257
SG&A (expenses)	(946)	(1,056)	(1,100)	(1,364)	(1,850)	(1,924)
R&D costs	(1,053)	(774)	(2,035)	(1,667)	(3,145)	(1,350)
Other income/(expense) included in adjusted	0	0	0	0	0	0
Other income/(expense) excluded from adjusted	0	0	0	0	0	0
Reported EBIT	(1,681)	(1,303)	(2,552)	(2,127)	(3,930)	(2,017)
Finance income/ (expense)	10	25	16	5	(70)	14
Other income/(expense) included in adjusted	0	(2)	2	7	0	0
Other income/(expense) excluded from adjusted	69	168	(95)	(195)	0	0
Reported PBT	(1,601)	(1,112)	(2,628)	(2,309)	(4,000)	(2,003)
Income tax expense	(4)	(4)	(4)	(4)	(4)	(4)
Reported net income	(1,605)	(1,116)	(2,632)	(2,313)	(4,003)	(2,006)
Average number of shares – basic (m)	23.2	30.8	32.4	39.3	47.2	48.0
Basic EPS (JPY)	(69.29)	(36.26)	(81.26)	(58.82)	(84.74)	(41.84)
Adjusted EBITDA	(1,672)	(1,291)	(2,527)	(2,101)	(3,903)	(1,987)
Adjusted EBIT	(1,681)	(1,303)	(2,552)	(2,127)	(3,930)	(2,017)
Adjusted PBT	(1,601)	(1,110)	(2,630)	(2,317)	(4,000)	(2,003)
Adjusted EPS (JPY)	(69.29)	(36.20)	(81.33)	(59.00)	(84.74)	(41.84)
Adjusted diluted EPS (JPY)	(69.29)	(36.20)	(81.33)	(59.00)	(84.74)	(41.84)
Balance sheet						
Property, plant and equipment	9	49	53	75	95	117
Goodwill	0	0	0	0	0	0
Intangible assets	8	66	52	42	35	29
Other non-current assets	37	49	53	77	77	77
Total non-current assets	53	164	158	193	206	223
Cash and equivalents	5,294	5,092	4,261	5,719	1,398	400
Inventories	125	245	133	273	347	328
Trade and other receivables	0	273	301	487	641	582
Other current assets	2,215	1,681	132	205	205	205
Total current assets	7,634	7,290	4,827	6,685	2,592	1,515
Non-current loans and borrowings	0	0	0	450	150	951
Trade and other payables	0	0	0	0	0	0
Other non-current liabilities	3	2	2	1	1	1
Total non-current liabilities	3	2	2	451	151	952
Trade and other payables	0	306	320	322	408	267
Current loans and borrowings	0	0	0	0	0	150
Other current liabilities	251	182	231	620	620	620
Total current liabilities	251	488	551	942	1,029	1,037
Equity attributable to company	7,433	6,964	4,432	5,485	1,618	(251)
Non-controlling interest	0	0	0	0	0	0
Cashflow statement						
Profit before tax	(1,601)	(1,112)	(2,628)	(2,309)	(4,000)	(2,003)
Depreciation and Amortisation	8	13	24	26	27	30
Share based payments	67	95	103	137	137	137
Other adjustments	(27)	(207)	26	197	70	(14)
Movements in working capital	(127)	(78)	190	(13)	(141)	(63)
Interest paid / received	7	27	18	6	(70)	14
Income taxes paid	(4)	(4)	(4)	(4)	(4)	(4)
Cash from operations (CFO)	(1,677)	(1,266)	(2,272)	(1,960)	(3,981)	(1,903)
Capex	0	(109)	(24)	(28)	(40)	(47)
Acquisitions & disposals net	0	0	0	0	0	0
Other investing activities	(1,332)	423	1,513	(16)	0	0
Cash used in investing activities (CFIA)	(1,332)	314	1,489	(44)	(40)	(47)
Net proceeds from issue of shares	4,057	544	(2)	3,226	0	0
Movements in debt	0	0	0	450	(300)	951
Other financing activities	(1)	(1)	(1)	(18)	0	0
Cash from financing activities (CFF)	4,057	544	(3)	3,658	(300)	951
Currency translation differences and other	7	206	(45)	(196)	0	0
Increase/(decrease) in cash and equivalents	1,054	(202)	(831)	1,458	(4,321)	(998)
Cash and equivalents at end of period	5,294	5,092	4,261	5,719	1,398	400
Net (debt) cash	5,294	5,092	4,261	5,269	1,248	(701)
Movement in net (debt) cash over period	1,054	(202)	(831)	1,008	(4,021)	(1,949)

Source: Edison Investment Research and SymBio Pharmaceuticals accounts

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Symbio Pharmaceuticals and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2017. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.